Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)
Others
Ratios

Benitec Biopharma (BNTC) EPS (Basic) (2019 - 2025)

Benitec Biopharma's EPS (Basic) history spans 7 years, with the latest figure at -$0.18 for Q1 2025.

  • For Q1 2025, EPS (Basic) fell 103.96% year-over-year to -$0.18; the TTM value through Mar 2025 reached -$5.09, down 35.37%, while the annual FY2024 figure was -$5.51, 60.98% up from the prior year.
  • EPS (Basic) for Q1 2025 was -$0.18 at Benitec Biopharma, up from -$0.33 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $4.54 in Q1 2024 and bottomed at -$36.27 in Q2 2022.
  • The 5-year median for EPS (Basic) is -$0.82 (2021), against an average of -$3.48.
  • The largest annual shift saw EPS (Basic) tumbled 18035.0% in 2022 before it skyrocketed 309.22% in 2024.
  • A 5-year view of EPS (Basic) shows it stood at -$0.59 in 2021, then plummeted by 123.73% to -$1.32 in 2022, then tumbled by 96.97% to -$2.6 in 2023, then skyrocketed by 87.31% to -$0.33 in 2024, then soared by 45.45% to -$0.18 in 2025.
  • Per Business Quant, the three most recent readings for BNTC's EPS (Basic) are -$0.18 (Q1 2025), -$0.33 (Q4 2024), and -$0.18 (Q3 2024).